APA (7th ed.) Citation

Shorr, A. F., Jones, M. E., Friedmann, S., Ionescu, D., Saulay, M., Smart, J. I., & Engelhardt, M. (2025). Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PLoS ONE, 20(6), 1. https://doi.org/10.1371/journal.pone.0326758

Chicago Style (17th ed.) Citation

Shorr, Andrew F., Mark E. Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I. Smart, and Marc Engelhardt. "Ceftobiprole Versus Ceftriaxone ± Linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a Randomized, Phase 3 Study Using 2020 FDA Guidance." PLoS ONE 20, no. 6 (2025): 1. https://doi.org/10.1371/journal.pone.0326758.

MLA (9th ed.) Citation

Shorr, Andrew F., et al. "Ceftobiprole Versus Ceftriaxone ± Linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a Randomized, Phase 3 Study Using 2020 FDA Guidance." PLoS ONE, vol. 20, no. 6, 2025, p. 1, https://doi.org/10.1371/journal.pone.0326758.